Global hyperhidrosis treatment market is anticipated to witness significant growth over the forecast period owing to the surge in the incidences of secondary hyperhidrosis condition globally. Rising incidences of secondary hyperhidrosis are associated with sedentary lifestyle, unhealthy diet, and alcohol habits that causes various diseased conditions such as hypoglycemia, hyperthyroidism, and anxiety. Hyperhidrosis is characterized by excessive sweating that occurs mainly in palms, soles, armpits, and face, but it also can affect chest, lower limb, abdomen, back, and inguinal regions. According to the study published in Journal of American Dermatology in 2017, an estimated prevalence of hyperhidrosis is 2.8% in the U.S. Moreover, the rise in research and developmental expenditure by the players operating coupled with promising pipeline for hyperhidrosis treatment will further boost the growth of the market in near future.
Global hyperhidrosis treatment market is segmented on the basis of type, treatment, distribution channel, and geography. The type segment includes primary focal and secondary generalized hyperhidrosis. Among type segment, secondary generalized is anticipated to register highest growth during forecast period. The secondary generalized hyperhidrosis is caused by any medical condition or due to side effect of any medication. Thus, growing prevalence of depression and anxiety globally is one of the key attributing factors for the growth of segment. In terms of treatment, the market is sub-segmented into topical treatment, Botulinum Toxin A, iontophoresis, surgical treatment, and others. Allergan’s Botox is the only approved treatment for primary focal hyperhidrosis that led to major share of the segment in 2017. Also, some of the key competitors for Botox such as, Xeomin and Dysport are also used off-label for the treatment. The distribution channel segment of hyperhidrosis treatment market further divided into h
ospital pharmacies, retail pharmacies and online pharmacies.
Geographically, the hyperhidrosis treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and MEA. North America dominated the market in 2017. The major factors that attributed towards its high share include increased diagnosis rate of hyperhidrosis coupled with availability of technologically advanced and sophistical advanced treatment options. Asia pacific region is expected to register highest growth rate during forecast period owing to rising awareness about hyperhidrosis coupled with surge in incidences of depression and anxiety in the region. According to the study ‘Depression and Other Common Mental Disorders’ published by WHO in 2017 an estimated 86 million people in South-East Asia are suffering from depression.
The prominent players in market are Allergan, Brickell Biotech, Inc., Dermira, Inc., GlaxoSmithKline plc, Revance Therapeutics, Inc., Ulthera, Inc., Dr. August Wolff GmbH, TheraVida. The companies operating in the market are focusing on R&D investments and fund raining activities to conduct clinical trials that lead to strong product pipeline. For instance, Revance Therapeutics, Inc’s RT002 and Brickell Biotech, Inc’s Sofpironium Bromide which is a topical anticholinergic are some of the products under clinical trial for the treatment of hyperhidrosis. As diagnosis rate and market penetration endure to expand, there are expectations for market growth during forecast period. Moreover, new product approvals in the market will further fuel market growth.
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.